[The treatment of dermatomycoses with Phebrocon].
D000935:Antifungal Agents / Q000627:therapeutic use*; D001431:Bacteriological Techniques; D002175:Candida / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy; D003470:Culture Media; D003881:Dermatomycoses / Q000188:drug therapy*; D004821:Epidermophyton / Q000187:drug effects; D006604:Hexylresorcinol / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009617:Nocardia Infections / Q000188:drug therapy; D009824:Ointments; D014009:Onychomycosis / Q000188:drug therapy; D010915:Pityriasis / Q000188:drug therapy; D011485:Protein Binding; D011552:Pseudomonas Infections / Q000150:complications; D011726:Pyridinium Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D011806:Quinolinium Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D014008:Tinea Pedis / Q000188:drug therapy; D014010:Tinea Versicolor / Q000188:drug therapy; D014249:Trichophyton / Q000187:drug effects; D014476:Undecylenic Acids / Q000494:pharmacology / Q000627:therapeutic use*
D000935:Antifungal Agents; D003470:Culture Media; D009824:Ointments; D011726:Pyridinium Compounds; D011806:Quinolinium Compounds; D014476:Undecylenic Acids; D006604:Hexylresorcinol
Zur Behandlung von Dermatomykosen mit Phebrocon.